Physician profile
Tulika Narain
NPI 1922066828
$659.86
in general payments reported to CMS, 2019-2025
9 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $118 · 2020: $54.01 · 2021: $80.08 · 2022: $106 · 2023: $233 · 2024: $69.32.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $302.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $301.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $249.26 | 2019-2024 | Gardasil 9, Vaxneuvance, Vaxelis |
| Glaxosmithkline, LLC. | $148.15 | 2019-2023 | Bexsero |
| Kaleo, INC. | $98.14 | 2019-2023 | Auvi-Q |
| Sanofi Pasteur INC. | $61.19 | 2023 | |
| Pfizer INC. | $43.11 | 2019-2023 | |
| Cumberland Pharmaceuticals, INC. | $16.44 | 2023 | Kristalose |
| Abbvie INC. | $15.41 | 2021 | |
| Sobi, INC | $14.29 | 2019 | |
| Exeltis, USA INC. | $13.87 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tulika Narain listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.